KCI Trials vs CARTOX

KCI Trials is a free mobile app from the Barbara Ann Karmanos Cancer Institute designed to help patients, caregivers, and healthcare professionals quickly find active cancer clinical trials open to accrual. Key Features • Powerful Trial Search: Find clinical trials by cancer type, protocol number or NCT ID, keyword, phase, principal investigator, study site, drug, device, therapy, or category. • Smart Filters: Apply multiple filters at once, with dynamically updated options to prevent dead end searches. • Instant Results—Even Offline: Daily data updates allow fast, on device searches, with full access to trial details even with limited or no connectivity. • Comprehensive Protocol Details: View objectives, eligibility criteria, treatments, locations, investigators, and related drugs. • Enhanced Drug Information: Explore enriched drug profiles powered by the NCI Drug Dictionary, including U.S. brand names. • Favorites & Saved Searches: Save trials and searches for quick access later—duplicates automatically prevented. • Easy Sharing: Share trial details via text or email, including summarized or full protocol information. • Location & Mapping Tools: View study site addresses, copy locations, and open directions directly in Maps. • Trusted Resources: Quick links to ClinicalTrials.gov and other National Cancer Institute resources. • Secure & Reliable: Independently penetration tested to ensure a safe and secure experience.

Cellular therapies can be associated with unique, acute toxicities which can be severe or even fatal if not identified early and treated appropriately. Cytokine Release Syndrome (CRS), the most commonly observed toxicity can range in severity from low-grade constitutional symptoms to high-grade syndrome associated with life-threatening multi-organ disfunction. Neurotoxicity, originally termed CRES (CAR-Related Encephalopathy Syndrome) and now updated to ICANS (Immune effector Cell-Associated Neurotoxicity Syndrome) is the second most-common adverse even and can occur concurrently with CRS. A multi-disciplinary working group was formed to address safety issues for patients receiving cellular therapy which led to the development of new grading methods and treatment algorithms that have been incorporated into the CARTOX mobile app. The CARTOX mobile app assists with grading toxicities, managing toxicities and assists with recommendations regarding appropriate antimicrobial prophylaxis for patients who have received immune effector cell therapy. Users are more easily able to determine if the patient is having cytokine release syndrome or neurotoxicity and to grade those toxicities. Intended audience: Clinicians (physicians, nurse practitioners, physician assistants, pharmacists, nurses) who treat/care for patients receiving immune effector cells.